Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y. · 2016
Read Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. by Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5340226.txt.
Description
Junko Murai, Ying Feng, Guoying K. Yu, Yuanbin Ru, Sai-Wen Tang, Yuqiao Shen, and Yves Pommier studied drug resistance in cancer cells in Oncotarget in 2016. A drug class called PARP inhibitors kills cancer cells by trapping a repair protein on DNA. One such drug worked with sharp force on some cell lines and not others, well past the known BRCA pattern. The team hunted the trait that split the lines.
A gene called SLFN11 fit the split. Cells that make it die under the drugs; cells that silence it shrug them off. Close to half of cancer cell lines have it off, which makes it a prime cause of resistance. The gene halts DNA copying in a lasting, lethal way when the trap springs. A second drug that blocks the ATR guard path broke the resistance, since cells without SLFN11 lean wholly on that path to live.
Catalog record
| CREATOR | Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |